Feb 4 (Reuters) - AbbVie forecast 2026 profit above Wall Street estimates on Wednesday after posting a fourth-quarter results ...
AbbVie stock falls 3.6% despite Q4 earnings beat of $2.71/share and 2026 guidance topping estimates as oncology and aesthetics revenue decline.
AbbVie extended the patent life on Humira for years, enough time to more than replace the sales. Now Merck and Bristol Myers ...
Alvotech (NASDAQ: ALVO), a global biotechnology company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced that it has entered into supply ...
We came across a bullish thesis on AbbVie Inc. on Disruptive Analytics ’ Substack by Magnus Ofstad. In this article, we will ...
Using same proprietary, patented technology, VIVI Med extends the product portfolio beyond injectable pens, opening access to broader patient populations, premium ...
Humira (adalimumab) is a biologic medication used to treat several chronic inflammatory conditions, including rheumatoid arthritis, Crohn’s disease, and plaque psoriasis. For years, it has been one of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results